|Study Description:||Why is this study being done?|
Moxetumomab pasudotox is an investigational agent that was developed to target
a particular molecule, CD22, that can be found on the surface of cancer cells
and to selectively kill the cells that have the molecule. Moxetumomab
pasudotox has not been approved by the Food and Drug Administration (FDA);
however, in an early clinical study of 48 patients with hairy cell leukemia who
had not responded to standard therapy, it has been shown to eliminate (26
patients) or reduce (16 patients) tumor cells. Overall 114 patients, both
children and adults, have been treated with moxetumomab pasudotox with limited
side effects which are discussed in the risks section of the consent.
The purpose of this study is to find how effective moxetumomab pasudotox is at
eliminating tumor cells for at least 6 months.